Ak-d101
Phase 3
Ak-d101 is one of 32 therapeutic programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
35 competitors in Attention Deficit Hyperactivity Disorder
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Strattera
MMap77
Approved
Vyvanse
TakedaApproved
Revia
TevaApproved
Depakote
TevaApproved
Nicorette
PfizerApproved
Intuniv
PPromius Pharma, LLC
Approved
Northera
LundbeckApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Brintellix
TakedaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Attention Deficit Hyperactivity Disorder1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Ak-d101. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- AAlvogen Korea